[go: up one dir, main page]

MA38126A1 - 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8 - Google Patents

6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8

Info

Publication number
MA38126A1
MA38126A1 MA38126A MA38126A MA38126A1 MA 38126 A1 MA38126 A1 MA 38126A1 MA 38126 A MA38126 A MA 38126A MA 38126 A MA38126 A MA 38126A MA 38126 A1 MA38126 A1 MA 38126A1
Authority
MA
Morocco
Prior art keywords
tarp
dependent
receptor antagonist
amfa
benzothiazol
Prior art date
Application number
MA38126A
Other languages
English (en)
Other versions
MA38126B1 (fr
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38126A1 publication Critical patent/MA38126A1/fr
Publication of MA38126B1 publication Critical patent/MA38126B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un antagoniste du récepteur ampa dépendant de tarp ?8 de formule : (i), ses sels pharmaceutiquement acceptables, ses utilisations et ses procédés de préparation.
MA38126A 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8 MA38126B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
PCT/US2013/070885 WO2014085153A1 (fr) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- éthyl)-3h-1,3-benzothiazol-2-one utilisable en tant qu'antagoniste du récepteur ampa dépendant de tarp-gamma

Publications (2)

Publication Number Publication Date
MA38126A1 true MA38126A1 (fr) 2017-03-31
MA38126B1 MA38126B1 (fr) 2017-11-30

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38126A MA38126B1 (fr) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8

Country Status (35)

Country Link
US (1) US8765960B2 (fr)
EP (1) EP2925754B1 (fr)
JP (1) JP6246227B2 (fr)
KR (1) KR101693133B1 (fr)
CN (1) CN104797578B (fr)
AP (1) AP2015008489A0 (fr)
AR (1) AR093527A1 (fr)
AU (1) AU2013352594B2 (fr)
BR (1) BR112015011200A2 (fr)
CA (1) CA2889243C (fr)
CL (1) CL2015001419A1 (fr)
CR (1) CR20150267A (fr)
CY (1) CY1118657T1 (fr)
DK (1) DK2925754T3 (fr)
DO (1) DOP2015000113A (fr)
EA (1) EA026686B1 (fr)
ES (1) ES2618260T3 (fr)
HR (1) HRP20170274T1 (fr)
HU (1) HUE033447T2 (fr)
IL (1) IL238831B (fr)
JO (1) JO3225B1 (fr)
MA (1) MA38126B1 (fr)
MX (1) MX356478B (fr)
MY (1) MY177721A (fr)
PE (1) PE20151728A1 (fr)
PH (1) PH12015501154B1 (fr)
PL (1) PL2925754T3 (fr)
PT (1) PT2925754T (fr)
SG (1) SG11201504164VA (fr)
SI (1) SI2925754T1 (fr)
TN (1) TN2015000200A1 (fr)
TW (2) TW201825484A (fr)
UA (1) UA114345C2 (fr)
WO (1) WO2014085153A1 (fr)
ZA (1) ZA201503733B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
CN107567452B (zh) 2015-04-29 2020-07-07 詹森药业有限公司 咪唑并哌嗪和吡唑并嘧啶以及它们作为ampa受体调节剂的用途
CA2984305C (fr) 2015-04-29 2021-12-28 Janssen Pharmaceutica Nv Composes indolones et utilisation de ces derniers en tant que modulateurs des recepteurs ampa
KR20170141767A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 벤즈이미다졸론 및 벤조티아졸론 화합물 및 ampa 수용체 조절제로서의 이들의 용도
HUE053943T2 (hu) 2015-04-29 2021-08-30 Janssen Pharmaceutica Nv Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk
CA3039676A1 (fr) * 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv Composes de pyridine bicyclique fusionnes et leur utilisation comme modulateurs des recepteurs ampa
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ａｍｐａ拮抗化合物の新規製造法
NZ522773A (en) * 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
US7838543B2 (en) * 2004-12-17 2010-11-23 Eli Lilly And Company MCH receptor antagonists
WO2007076161A2 (fr) 2005-12-27 2007-07-05 Myriad Genetics, Inc Composés ayant une activité thérapeutique
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
WO2010041162A1 (fr) * 2008-10-08 2010-04-15 Pfizer Inc. Tétrahydrofuranylsulfonamides destinés à être utilisés en tant que modulateurs d'ampa dans le traitement de troubles du snc
CN102348697B (zh) * 2009-01-12 2014-12-10 辉瑞股份有限公司 磺酰胺衍生物
AU2011261586B2 (en) * 2010-06-01 2015-08-27 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
JP5976011B2 (ja) * 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物

Also Published As

Publication number Publication date
EP2925754A1 (fr) 2015-10-07
AU2013352594B2 (en) 2016-02-18
IL238831A0 (en) 2015-06-30
ES2618260T3 (es) 2017-06-21
CN104797578B (zh) 2016-11-23
PH12015501154A1 (en) 2015-08-10
PL2925754T3 (pl) 2017-07-31
AP2015008489A0 (en) 2015-05-31
BR112015011200A2 (pt) 2017-07-11
TN2015000200A1 (en) 2016-10-03
JP6246227B2 (ja) 2017-12-13
MX356478B (es) 2018-05-30
WO2014085153A1 (fr) 2014-06-05
US20140148441A1 (en) 2014-05-29
HRP20170274T1 (hr) 2017-04-07
CL2015001419A1 (es) 2015-10-02
CY1118657T1 (el) 2017-07-12
DOP2015000113A (es) 2015-06-15
MY177721A (en) 2020-09-23
HUE033447T2 (en) 2017-11-28
ZA201503733B (en) 2017-09-27
SG11201504164VA (en) 2015-07-30
UA114345C2 (uk) 2017-05-25
CA2889243A1 (fr) 2014-06-05
CA2889243C (fr) 2017-06-13
EA026686B1 (ru) 2017-05-31
EA201590823A1 (ru) 2015-08-31
AR093527A1 (es) 2015-06-10
CR20150267A (es) 2015-09-16
CN104797578A (zh) 2015-07-22
AU2013352594A1 (en) 2015-06-04
SI2925754T1 (sl) 2017-02-28
DK2925754T3 (en) 2017-02-20
HK1209116A1 (en) 2016-03-24
IL238831B (en) 2018-08-30
JP2016501219A (ja) 2016-01-18
MX2015006697A (es) 2015-08-05
JO3225B1 (ar) 2018-03-08
MA38126B1 (fr) 2017-11-30
KR101693133B1 (ko) 2017-01-04
TW201825484A (zh) 2018-07-16
US8765960B2 (en) 2014-07-01
WO2014085153A8 (fr) 2014-07-31
PH12015501154B1 (en) 2018-05-30
TWI618705B (zh) 2018-03-21
KR20150070401A (ko) 2015-06-24
EP2925754B1 (fr) 2016-12-28
TW201434834A (zh) 2014-09-16
PT2925754T (pt) 2017-02-27
PE20151728A1 (es) 2015-12-02

Similar Documents

Publication Publication Date Title
MA38126B1 (fr) 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA37405A1 (fr) Composés hétérocyclyle
MA33492B1 (fr) Inhibiteurs de bace
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
EA201270339A1 (ru) Замещенные производные ксантина
MX2012006909A (es) LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
PH12020550905A1 (en) Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
TN2014000519A1 (en) Pyrimidinone derivatives as antimalarial agents
MA34663B1 (fr) Composés 3-phénylsulfanylméthyl-bicyclo[3.1.0]hexane 4-substitués en tant qu'antagonistes de mglur 2/3
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
MA33828B1 (fr) Dérivés 8-hydroxyquinoline-7-carboxamide secondaires et leurs utilisations en tant qu'agents antifongiques
PH12013500588A1 (en) Indole derivatives
WO2012015687A3 (fr) Conjugués médicament-ligand, leur synthèse et leurs intermédiaires